ESMO 2023 | MOUNTAINEER: clinical relevance of genomic profiling for tucatinib + trastuzumab treatment in mCRC

John H. Strickler, MD, Duke Cancer Institute, Durham, NC, discusses the clinical implications of the Phase II MOUNTAINEER (NCT03043313) trial, which explored genomic alterations that may predict sensitivity or resistance to tucatinib plus trastuzumab in patients with HER2+ metastatic colorectal cancer (mCRC). He highlights how genomic profiling with next-generation sequencing (NGS) enables identification of patients who are likely to respond to the regimen. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.